Medtronic plc (MDT) recently presented a set of new clinical and real-world evidence on the MiniMed 780G system from around the world. The latest data reveals that the system withstands strong global performance, exceeding international targets for diabetes management.The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy.Study DetailsAccording to the business, the findings are built on three years of data published in Diabe ...